11,500 Shares in Stryker Corporation $SYK Acquired by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB bought a new stake in shares of Stryker Corporation (NYSE:SYK) during the second quarter, HoldingsChannel reports. The fund bought 11,500 shares of the medical technology company’s stock, valued at approximately $4,550,000.

A number of other institutional investors also recently made changes to their positions in the stock. Nuveen LLC acquired a new stake in shares of Stryker during the first quarter valued at $558,075,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after purchasing an additional 1,021,496 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock worth $511,152,000 after buying an additional 549,643 shares in the last quarter. ABN AMRO Bank N.V. acquired a new position in shares of Stryker in the second quarter valued at approximately $191,047,000. Finally, Vanguard Group Inc. lifted its stake in shares of Stryker by 1.3% during the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock valued at $13,253,831,000 after buying an additional 440,607 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

Stryker stock opened at $375.11 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm’s fifty day moving average price is $369.22 and its 200 day moving average price is $380.55. The company has a market capitalization of $143.45 billion, a price-to-earnings ratio of 49.68, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the prior year, the business posted $2.87 earnings per share. Stryker’s revenue for the quarter was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SYK has been the subject of several recent analyst reports. Truist Financial lifted their target price on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research note on Friday, November 14th. UBS Group set a $408.00 price objective on shares of Stryker in a research note on Monday, October 13th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research report on Wednesday, November 19th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Finally, Rothschild & Co Redburn started coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective for the company. Thirteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $434.37.

Insider Activity at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 522,118 shares of company stock valued at $185,381,932 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.